These properties are of importance based on recent murine studies showing the Jak2 inhibitor WP1193 can augment immunotherapy with IFN-α [42], and STAT3 siRNA-CpG oligodeoxynucleotides can elicit anti-tumor immune responses [43]. This evidence concerns the gene JAK2 and neoplasm.